MedTrace Logo

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

NCT02270034 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-03-10

No results posted yet for this study

Summary

This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.

Conditions

  • Glioblastoma Multiforme (Grade IV) of Cerebellum

Interventions

DRUG

Crizotinib

Crizotinib is added to Stupp method

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Grupo Español de Investigación en Neurooncología

    lead OTHER

Principal Investigators

  • Juan Manuel Sepúlveda, MD · Hospital 12 de Octubre

  • María Martínez, MD · Hospital del Mar

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-13
Primary Completion
2020-10-26
Completion
2020-10-26

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02270034 on ClinicalTrials.gov